ArticleFrontiers in pharmacology2025

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer in China.

Yibing Hou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.